Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03810638 · ClinicalTrials.gov registry record

Creation of a Digital Heart Failure Registry Using a Novel Mobile Health Platform: HUGO-HF

A clinical trial of Heart Failure, sponsored by Yale University.

Completed
Registry status
85
Enrollment target
1
Study location

NCT03810638: Completed study of Heart Failure, sponsored by Yale University.

NCT03810638 is a study of Heart Failure that has completed, run by Yale University. The registered enrollment target is 85 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03810638, a study of Heart Failure, has completed, sponsored by Yale University.

COMPLETED
Registry status
85 participants
Enrollment target
1
Study location

Study Summary

The investigators goal is to create a digital registry that allows for seamless integration of patient reported outcomes, electronic health record data, and pharmacy information into data collection. The investigators will accomplish this using a novel patient centered mobile health platform called Hugo that will allow them to engage patients in an entirely novel manner.

Primary Outcome

Short Version of the KCCQ will be used. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is the most validated instrument to measure quality of life in heart failure.

Conditions Studied

Study Locations (1)

Connecticut

  • Yale New Haven Hospital - New Haven

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2019-01-15
Est. Completion 2019-12-31
Yale University

1,492 total trials

What the finished NCT03810638 record still lists

NCT03810638 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 0 interventions.

NCT03810638 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT03810638 about?

NCT03810638 is a clinical study titled "Creation of a Digital Heart Failure Registry Using a Novel Mobile Health Platform: HUGO-HF". The investigators goal is to create a digital registry that allows for seamless integration of patient reported outcomes, electronic health record data, and pharmacy information into data collection. The investigators will accomplish this using a novel patient centered mobile health platform called ...

What is the current status of trial NCT03810638?

This trial is currently completed. The enrollment target is 85 participants. The study started on 2019-01-15. Estimated completion is 2019-12-31.

What conditions does trial NCT03810638 study?

This clinical trial studies the following conditions: Heart Failure.

Who is sponsoring clinical trial NCT03810638?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03810638 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03810638's enrollment target sits among peer trials

85 226th of 397 higher than 171 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00842283 · 85 participants

    Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

  • NCT02133196 · 85 participants · Phase 2

    T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

  • NCT03823144 · 85 participants · NA

    Intravital Microscopy in Human Solid Tumors

  • NCT03875638 · 85 participants · Phase 2

    Treating Hyperexcitability in AD With Levetiracetam

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03810638, the US trial registry maintained by the National Library of Medicine. NCT03810638 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.